Washington Roundup
Executive Summary
The latest medical device regulatory and reimbursement news from Elsevier Business Intelligence's "The Gray Sheet."
You may also be interested in...
Total Joint Market: Slowly Recovering
The $13 billion total joint market is facing a number of challenges coming off the recent recession. Although the demographics related to joint replacement remain strong, manufacturers continue to be plagued by downward pressure on implant prices, a slowdown in procedure volumes, and an ongoing shift in hospital purchasing. Many believe that J&J's recent acquisition of Synthes will spark a wave of consolidation in the industry.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.